We are live on ! Find out more
ALGS icon

Aligos Therapeutics
ALGS

35 hedge funds and large institutions have $19.2M invested in Aligos Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.05% less ownership

Funds ownership: 2.6% → 2.55% (-0.05%)

15% less funds holding

Funds holding: 41 → 35 (-6)

25% less capital invested

Capital invested by funds: $25.5M → $19.2M (-$6.3M)

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
35
Holders Change
-6
Holders Change %
-14.63%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
3
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$17.7K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$14.1K
3
Creative Planning
Creative Planning
Kansas
+$8.91K
4
UBS Group
UBS Group
Switzerland
+$4.7K

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$174K
2
Renaissance Technologies
Renaissance Technologies
New York
-$96.8K
3
Millennium Management
Millennium Management
New York
-$74.5K
4
Deutsche Bank
Deutsche Bank
Germany
-$69.2K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$50.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$2.95M – – –
VC
2
Vivo Capital
California
$2.65M – – –
TCM
3
Tang Capital Management
California
$2.49M – – –
VVM
4
Versant Venture Management
California
$1.73M – – –
HA
5
HHLR Advisors
Cayman Islands
$1.73M – – –
BBA
6
Baker Bros. Advisors
New York
$1.55M – – –
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$914K – – –
Bank of America
8
Bank of America
North Carolina
$859K -$643 -29 -0.1%
Vanguard Group
9
Vanguard Group
Pennsylvania
$755K +$14.1K +637 +2%
NM
10
Newtyn Management
New York
$687K +$17.7K +800 +2%
PBPIA
11
Pivotal bioVenture Partners Investment Advisor
California
$555K – – –
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$481K -$174K -7,834 -23%
SCM
13
Silverarc Capital Management
Massachusetts
$472K – – –
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$420K – – –
Renaissance Technologies
15
Renaissance Technologies
New York
$240K -$96.8K -4,368 -25%
BlackRock
16
BlackRock
New York
$222K -$3.13K -141 -1%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$180K -$13.4K -604 -6%
State Street
18
State Street
Massachusetts
$72.8K – – –
BCM
19
Bridgeway Capital Management
Texas
$68.7K – – –
Millennium Management
20
Millennium Management
New York
$68.6K -$74.5K -3,363 -48%
Northern Trust
21
Northern Trust
Illinois
$29.4K – – –
Charles Schwab
22
Charles Schwab
California
$23.4K – – –
CIA
23
Choate Investment Advisors
Massachusetts
$17.9K – – –
Two Sigma Investments
24
Two Sigma Investments
New York
$17.1K -$5.54K -250 -21%
HP
25
Harbourvest Partners
Massachusetts
$14K – – –
1
2

ALGS Hedge Fund Activity: Q3 2023 in Review

35 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2023, worth a combined $19.2M — down 25% from $25.5M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ALGS and 1 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 3 added.

The largest buyer was Newtyn Management, adding an estimated $17.7K. The largest seller was Royal Bank of Canada, cutting an estimated $174K.

  • 35 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2023, down from 41 in Q2 2023.
  • Funds reported $19.2M of Aligos Therapeutics stock for Q3 2023, down 25% quarter-over-quarter.
  • 1 fund opened new Aligos Therapeutics positions in Q3 2023 and 7 closed out, a net change of -6 holders.
  • The largest Aligos Therapeutics buyer in Q3 2023 was Newtyn Management, an estimated $17.7K added.
  • The largest Aligos Therapeutics seller in Q3 2023 was Royal Bank of Canada, an estimated $174K sold.

Based on aggregated 13F filings for Q3 2023.